Chemical modifications of striatal A2A adenosine receptors: a possible role for tyrosine at the ligand binding sites  by Martini, Claudia et al.
 .Biochimica et Biophysica Acta 1326 1997 67–74
Chemical modifications of striatal A adenosine receptors: a possible2A
role for tyrosine at the ligand binding sites
Claudia Martini ), Letizia Trincavelli, Antonio Lucacchini
Istituto Policattedra di Discipline Biologiche, Uni˝ersita di Pisa, Via Bonanno 6, 56126 Pisa, Italy`
Received 8 July 1996; revised 23 October 1996; accepted 20 November 1996
Abstract
 .A adenosine receptors were examined in bovine striatal membranes following exposure to tetranitromethane TNM2A
 .which modifies tyrosine and cysteine residues. TNM 0.05–0.5 mM treatment caused an irreversible, concentration-depen-
w3 xdent decrease in the binding activity of the selective A agonist H CGS 21680. Protection studies showed that TNM2A
X  .inactivation could be prevented by the adenosine receptor agonist 5 -N-ethylcarboxamidoadenosine NECA and by the
 .antagonist xanthine amine congener XAC , suggesting that TNM modified residues at the ligand-binding sites. Scatchard
w3 xanalysis of the binding data showed that 0.15 mM TNM decreased the H CGS 21680 B value from 447"39 tomax
273"21 fmolrmg of proteins without any significant change in the K values 13.5"1.4 and 14.7"1.5 for control andd
.treated membranes, respectively . We carried out a series of successive chemical modifications with the reducing agent
 .dithiothreitol DTT , which indicated that the residues modified by TNM, under our experimental conditions, are tyrosine
residues and not cysteine residues.
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1. Introduction
Adenosine acts as a neuromodulator in the central
and peripheral nervous system and as a homeostatic
regulator in a variety of other tissues, including heart,
w xkidney and immune system 1 . These effects involve
a receptor-mediated mechanism including direct in-
teraction with second messenger systems via G pro-
. w x w xteins 2,3 , transmembrane ion fluxes 4 and neuro-
w xtrasmitter release 5,6 . Four subtypes of adenosine
 .receptors ARs , referred to as A , A , A and A ,1 2A 2B 3
w xhave been cloned and expressed 7 from several
) Corresponding author. Fax. q39-50-40517; E-mail: cmar-
tini@farm.unipi.it
w x w xspecies including rats 8–11 , dogs 12,13 , mice and
w xhumans 14 .
Pharmacologically, the A receptor is associated2A
w x w xwith hypotensive 15 , immnunosuppressive 16 ,
w xplatelet antiaggregatory 17 and locomotor depres-
w xsant effects 18 .
Relatively little is known about the biochemistry
of A ARs as a whole, and even less about the2A
w xligand-binding site itself. A model 19 featuring
seven transmembrane helices characteristic of G pro-
tein-linked receptors, based on structural analysis of
canine A ARs, has been proposed. Briefly, this2A
model predicts that the receptor consists of seven
alpha-helical membrane-spanning domains connected
by three extracellular and three intracellular loops;
the N- and C-termini of the protein are situated on
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the extracellular and intracellular sides of the plasma
membrane, respectively. Furthermore, A ARs con-2A
tain several features common to all G-protein-cou-
pled receptors which display this structure: these
include the presence of cysteine residues on the
extracellular loops which, by analogy with other re-
ceptors, may be involved in disulfide bond formation.
w3 xA sensitivity of H CGS 21680 binding in rabbit
striatum to the reducing agents dithiothreitol and
sodium dithionite suggests that such bonds are pre-
w xsent in A ARs 20 . A role for histidine residues in2A
mediating ligand-binding at A ARs has been sug-2A
 .gested by the ability of diethylpyrocarbonate DEP ,
a His-reactive compound, to diminish both the ago-
w3 x w3 xnist H CGS 21680 and the antagonist H XAC
w xbinding in treated rabbit striatal membranes 20 .
The aim of this study was to further characterize
w3 xthe site of interaction of the agonist H CGS 21680
with A ARs, in bovine striatum, by treatment with2A
 .tetranitromethane TNM .
TNM has been shown to be a convenient reagent
w xfor the nitration of tyrosine residues in proteins 21 ,
although specificity studies have shown that other
residues, in particular sulfhydryl groups, are poten-
tially reactive towards TNM.
2. Materials and methods
w3 x  .H CGS 21680 47.2 Cirmmol was obtained
from Dupont–New England Nuclear Boston, MA,
.USA ; Adenosine deaminase, NECA and XAC were
purchased from Boehringer-Mannheim Mannheim,
.Germany ; TNM and other chemicals were obtained
from Sigma Chemical Company St Louis, MO,
.USA .
2.1. Membrane preparation
Bovine striatal membrane preparation was per-
w xformed as previously described 22 . Briefly, the
tissue was homogenised in 20 volumes of ice-cold 50
mM Tris HCl buffer at pH 7.5 containing 10 mM
 .MgCl T in the presence of protease inhibitors2 1
160 mgrml benzamidine, 20 mgrml soybean trypsin
.inhibitor and 200 mgrml bacitracine and centrifuged
at 48 000=g for 10 min at 48C. The resulting pellet
was resuspended in T buffer containing protease1
inhibitors and 2 IUrml of adenosine deaminase and
incubated at 378C for 30 min to remove endogenous
adenosine.
This preparation was recentrifuged and the final
pellet was frozen at y708C until the time of assay.
2.2. TNM treatment
Nitration of striatal membranes 2–3 mgrml pro-
.teins was performed with TNM at pH 8.1 as previ-
w xously described 23 . Briefly, aliquots of TNM in
ethanol were added to the receptor preparations to
yield a final TNM concentration of 0.05–0.5 mM in
2% ethanol. Control membranes were subjected to
the same procedure, but only ethanol was added.
Incubation with gentle mixing was carried out at
constant pH, at room temperature for 30 min. Follow-
ing incubation with TNM, the membrane suspensions
were pelleted by centrifugation and washed three
times with reaction buffer, 50 mM Tris HCl at pH 8.1
 .  .1:20 T to remove the excess of the reagent.2
In order to evaluate the site specificity of the
w3 xinactivation reaction, the protection of H CGS
21680 binding against TNM modification was inves-
tigated as follows: membranes were preincubated
 .  .separately with NECA 1 mM or XAC 5 mM , and
then 0.15 mM TNM was added to the samples. At the
end of the modification reaction, membranes were
centrifuged and the ligands were removed by wash-
ing. Control samples were prepared by incubating
aliquots of membranes in the same experimental con-
ditions without the reagent.
TNM modification and protection experiments
were carried out with the same procedure at pH 6.5
too.
In some experiments, treatment with DTT, a
 .sulfhydryl reagent 10 mM , preceded or followed the
nitration step. This treatment was carried out at 258C,
pH 8.1, for 30 min and was separated from the
nitration step by washing of the membranes in buffer
T .2
2.3. Radioligand binding
w3 xThe H CGS 21680 binding assay was carried out
w xin triplicate as previously described 24 . Briefly,
 .aliquots of striatal membranes 0.3 mg of proteins
w3 xwere incubated in 500 ml T buffer with H CGS1
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 .21680 5 nM , both in the presence and in the
 .absence of unlabeled NECA 100 mM for non-
specific binding determination. After 90 min at 258C,
the binding reaction was stopped by filtration through
Whatman GFrC fiber glass filters, and then five
washes with 5 ml ice-cold buffer were performed.
Modification by TNM was evaluated by assaying
w3 xthe H CGS 21680 binding to control and treated
membranes.
w3 xSaturation analysis of H CGS 21680 binding sites
was performed on control and treated membranes
using 1.6–46 nM radioligand concentrations.
For competition studies, 6–8 different concentra-
tions of the agonist NECA or the antagonist XAC
were incubated with the T buffer containing 5 nM1
w3 xH CGS 21680, both in control and in TNM-treated
membranes.
Protein concentration was determined by the
w xmethod of Lowry et al. 25 using bovine serum
albumin as a standard.
2.4. Data analysis
Statistical analysis and curve-fitting were carried
out on an IBM-compatible personal computer using
the non-linear multipurpose curve-fitting program KI-
w xNETICS, EBDA and LIGAND 26 , from which the
 .values of K , the dissociation constant K and theob d
 .maximum number of receptor sites B were gen-max
 .erated. Accordingly, a partial F test P-0.01 was
used to determine whether the binding data were best
fitted by a one- or two-site model. IC values were50
derived from semilog plots of data from
agonistrantagonist displacement experiments. The
Cheng-Prusoff equation was used to calculate K i
w xvalues from IC values 27 . Values represent the50
 .means"SE derived from n experiments conducted
in triplicate. The difference among binding parame-
ters obtained in untreated and TNM-treated mem-
branes was evaluated by one-way analysis of vari-
 .ance ANOVA .
3. Results
3.1. Effects of TNM treatment on radioligand binding
The chemical modification of A ARs by TNM,2A
carried out as described in the Material and Methods
w3 xsection, resulted in a significant loss of H CGS
21680 binding activity, which was both concentra-
tion- and time-dependent.
After 15 min, a nearly complete loss of A AR2A
 .activity was obtained with 0.5 mM TNM Fig. 1 .
w3 xThe IC value of TNM for inhibition of H CGS50
21680 binding was found to be 0.18"0.013 mM.
When BrB B is the binding after pretreatmento
of membranes with TNM for the periods indicated,
.and B is control binding was plotted on a logarith-o
mic scale, the decrease appeared to be linearly related
 .to the preincubation time Fig. 2 . Therefore, the
inactivation proceeded according to apparent first-
 .order kinetics. The apparent first-order constant Kob
is defined by the equation ln BrB syK t, aso ob
shown in Fig. 2.
 .Exposure to 2% ethanol alone control resulted in
a slight drop of binding activity over the same time
course.
The reduction in agonist-binding induced by TNM
could be due to maximum binding or affinity decre-
ment, or both factors together. To establish which of
these factors were affected after TNM treatment,
equilibrium parameters of agonist-binding were as-
sayed by saturation analysis. The data were analyzed
w xin accord with the Scatchard method 28 , and are
shown in Fig. 3. The one-site model provided a
Fig. 1. Concentration dependence of the inactivation of A ARs2A
by TNM. Membranes were preincubated with increasing concen-
 .trations of TNM 0.05–0.5 mM for 15 min at 258C, washed
w3 xthree times with reaction buffer and incubated with 5 nM H CGS
21680. The subsequent binding assay involved 90 min incubation
followed by rapid filtration. Values represent means"standard
errors of three separate experiments.
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w3 xFig. 2. Time-dependent inactivation of H CGS 21680 binding
 .sites by TNM. Membranes were pretreated with: B only 2%
 .  .ethanol in buffer, control; v 0.1 mM TNM and ’ 0.2 mM
TNM for the periods of time indicated at 258C, washed and
w3 xassayed with H CGS 21680 as described in Section 2. Control
w3 xbinding referred to binding of H CGS 21680 to membranes
treated as described in Section 2. The pseudo-first order rate
constants calculated from the slopes of the lines shown are
1.3=10y2 "7.8=10y4 and 2.8=10y2 "1.9=10y3 miny1.
Values represent means"standard errors of at least six determi-
nations carried out in triplicate.
Fig. 3. Representative Scatchard plots of specifically bound
w3 x  . H CGS 21680 to control B and 0.15 mM TNM-treated 30
.  . min ’ membrane preparations. The membranes 0.3 mg of
.proteins were incubated in triplicate with increasing concentra-
w3 x  .tions of H CGS 21680 1.6–46 nM in the absence and in the
 .presence of unlabeled NECA 100 mM for 90 min at 258C as
w3 xdescribed in Section 2. The data of specifically bound H CGS
w x21680 were plotted according to Scatchard 28 . Data are from a
single experiment carried out in triplicate. Three such experi-
ments yielded similar results.
Fig. 4. Protection from inactivation by TNM. Membranes were
preincubated with buffer alone as control, with 1 mM NECA or 5
mM XAC for 10 min. Then 0.15 mM TNM-treatment for 30 min
was performed as described in Section 2. After extensive wash-
w3 xing, the binding of H CGS 21680 was determined. Data points
are means"standard errors of three experiments carried out in
w3 xtriplicate and are presented as the percentage of specific H CGS
21680 binding versus control.
 .significantly P-0.05 better fit and allowed detec-
tion of high affinity binding sites both in control and
in TNM-treated membranes. Exposure of bovine A 2A
ARs to 0.15 mM TNM for 30 min caused a signifi-
w3 xcant decrease in the maximum density of H CGS
21680 binding sites against the control value 273"
.21 vs. 477"39 fmolrmg of proteins respectively
 .Ps0.025 . By contrast, the chemical modification
w3 xhad no effect upon the K of the H CGS 21680d
binding to A ARs 13.5"1.4 nM for control and2A
.14.7"1.5 nM for treated membranes .
The addition of specific adenosine receptor lig-
ands, 1 mM NECA or 5 mM XAC, to the preincuba-
tion medium, was significantly suitable to prevent the
w3 xinactivation of H CGS 21680 radioligand binding
 . Fig. 4 Ps0.0057 for TNMqNECA and Ps
.0.0036 for TNMqXAC . As shown, both the ago-
nist and the antagonist had the same ability to protect
w3 xH CGS 21680 binding sites by inactivation.
 .Fig. 5 panels A and B shows the displacement of
w3 xH CGS 21680 binding to control and 0.15 mM
TNM treated membranes by increasing concentra-
tions of NECA and XAC. The shape of the displace-
ment curve was not significantly altered for either
ligand by chemical modification; the K values fori
NECA were 14"1.1 nM and 12.3"1.0 nM in
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w3 xFig. 5. Inhibition curves of H CGS 21680 displaced by NECA
 .  .panel A and XAC panel B to bovine striatal A ARs before2A
and after TNM treatment. Binding was carried out after 30 min
 .preincubation at 258C in the presence of 0.15 mM TNM ’ and
 .in control membranes B . Membranes were washed three times
with reaction buffer before radioligand binding. Membranes were
incubated with the radioligand at 258C for 90 min. Data points
are means"standard errors of three experiments conducted in
triplicate.
control and treated membranes, respectively, and for
XAC they were 50"4.2 nM and 58"4.9 nM, re-
spectively.
To demonstrate that TNM inactivation of A 2A
ARs was due to the nitration of tyrosine residues at
the ligand binding site andror oxidation of SH
groups, we carried out a series of successive chemical
modifications of the membranes.
If TNM treatment at pH 8.1 induced oxidation of
SH to S–S at the binding site, the reducing agent
DTT should restore their original properties. As
shown in Table 1, the sulfhydryl-reducing agent DTT
 .10 mM did not restore the properties of TNM-mod-
Table 1
Combined effects of TNM and DTT on A adenosine receptors2A
from bovine striatal membranes
3w xH CGS 21680 bindingMembrane preincubation
 .% of control
First Second
preincubation preincubation
Buffer Buffer 100"7.0
TNM Buffer 37"2.1
TNM DTT 35"1.9
DTT Buffer 61"4.8
DTT TNM 17"1.1
 .Membranes were preincubated with buffer or TNM 0.2 mM or
 .DTT 10 mM for 30 min at 258C and washed as described in the
text. Then, a second incubation with buffer or with indicated
compounds were performed followed by washings as indicated.
Aliquots of control and treated membranes were monitored by
w3 xH CGS 21680 binding. Data are means"standard error of three
experiments.
ified receptors. Furthermore, pretreatment with DTT
 .protecting the sulfhydryl groups did not prevent
TNM inactivation. These results would appear to
exclude the possibility that TNM modified cysteine
 .residues in our experimental conditions at pH 8.1 .
w3 xFig. 6. Inactivation of H CGS 21680 binding sites by TNM at
pH 6.5 and protection by NECA and XAC. Membranes were
preincubated with buffer alone, with 1 mM NECA or 5 mM XAC
for 10 min. Then 0.15 mM TNM treatment for 15 min was
performed as described in Section 2. After extensive washing, the
w3 xbinding of H CGS 21680 was determined. Data points are
means"standard errors of three experiments carried out in tripli-
w3 xcate and are presented as the percentage of specific H CGS
21680 binding versus control.
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The nitration of tyrosine residues is expected to
proceed much more slowly at pH 6.5 than at pH 8.1,
whereas the oxidation of cysteine is efficient at the
w xlower pH 21 . Unexpectedly, when we subjected an
aliquot of the membrane receptor preparation to treat-
ment with 0.15 mM TNM at pH 6.5 the loss of
w3 xH CGS 21680 binding activity was more marked
w3 xthan at pH 8.1: 30% of H CGS 21680 binding
capacity was lost after 15 min at pH 8.1 while the
 .corresponding value at pH 6.5 was 80% Fig. 6 .
The inhibition of radioligand binding by TNM at
pH 6.5 was not significantly prevented by the addi-
tion of A AR ligands, 1 mM NECA or 5 mM2A
 .XAC, to the preincubation medium Fig. 6 . This
suggests that the residues that can be modified at this
pH, probably cysteines, are not located at the
w3 xH CGS 21680 adenosine-binding sites.
4. Discussion
Over the past few years, the synthesis of adenosine
derivatives as agonists, and xanthine and non-xanthine
derivatives as antagonists has made it possible to
carry out a rigorous examination of the molecular
structure and regulation of adenosine receptors. The
subsequent use of gene cloning and molecular biol-
ogy technology has advanced insight into the molecu-
lar characteristics of these receptors, such as their
primary sequence, structural homology between
species, distribution in tissues and cellular expres-
sion. A pivotal point in the field of purinergic recep-
tors was the cloning and expression of RDC7 and
RDC8 from a dog thyroid cDNA library, using a
screening strategy based on sequence homology with
other G-protein-coupled receptors. RDC7 and RDC8
were found to encode the A and A adenosine1 2
receptor subtypes, respectively, through expression in
COS and CHO cells in which functional coupling to
adenylyl cyclase and radioligand binding was demon-
w xstrated 29,30 .
A considerable body of work studying the binding
at cloned biogenic amine receptors particularly
.adrenergic and muscarinic receptor subtypes has
demonstrated the importance of the amino acids pre-
sent in the transmembrane-spanning regions in medi-
w xating agonist and antagonist recognition 31 .
Owing to the proteic nature of these receptor sites,
their chemical modification by protein-group selec-
tive reagents may disclose the chemical topography
of the recognition sites and their regulatory interrela-
tionship as well. In the present study, we used TNM
as a modifying reagent in a receptor–ligand assay to
delineate specific tyrosine residues involved in high-
w3 xaffinity H CGS 21680 binding and A ARs. Un-2A
der mild conditions, in a pH-dependent fashion, at pH
8.1 and above, TNM is an efficient, specific reagent
for the nitration of tyrosine residues.
The treatment of A ARs with TNM at pH 8.12A
w3 xcaused an irreversible loss of H CGS 21680 bind-
ing activity of more than 90%. The loss of the
binding activity could be reduced if exposure of
receptors to chemical modification was performed
after preincubation with ligands which occupied the
ligand-binding site. Both the agonist NECA and the
antagonist XAC were able to protect the receptor
against TNM inactivation. These results indicated a
direct, rather than allosteric, effect of the TNM agent
upon the ligand site of A ARs, suggesting the2A
existence at the binding sites of TNM-modified
residues with an important role, for both agonist and
antagonist binding.
The results of saturation studies for A ARs2A
showed that TNM treatment reduced the number of
w3 xH CGS 21680 binding sites, with no change in the
affinity for the agonist. Furthermore, the binding site
characteristics before and after TNM treatment were
investigated by competition experiments with the ag-
onist NECA and the antagonist XAC. The affinity
 .constant K obtained for both ligands in native andi
TNM-modified receptors was unchanged.
These results provided evidence that TNM modifi-
cation was specific and occurred in or near the
binding sites of A ARs, probably without any2A
conformational change.
Also A adenosine receptors were modified by1
w xTNM treatment, as reported by Klotz et al. 32 . As
the inactivation of agonist and antagonist binding
could not be prevented by adenosine receptor ligands,
the modification probably does not occur at the A1
binding sites.
Recently, Ijzerman and co-workers have described
a three-dimensional model for rat A ARs, using the2A
A amino-acid sequence and the atomic coordinates2A
w xof bacteriorhodopsin 33 . This model predicted the
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presence in the A a receptor of a hydrophobic do-2
main, consisting of Ile139, Phe177, Phe252, Cys249 and
Tyr174, which is responsible for A selectivity. These2A
data could justify the different effects obtained by the
chemical modification of tyrosine residues for A and1
A receptors.2
TNM is well known for its ability to nitrate tyro-
sine residues as well as to oxidize free sulfhydryl
groups. A number of successive chemical modifica-
tions were performed in order to determine whether
cysteine residues are involved in the nitration proce-
dures.
As summarized in Table 1, the protection of the
S–H groups obtained with DTT pretreatment did not
account for the functional consequences of TNM
treatment. Preincubation with the sulfhydryl-reducing
w3 xagent induced a decrease in H CGS 21680 binding
probably due to the reduction of the S–S bonds
.present in A ARS without any effects on TNM2A
inactivation. In fact, TNM induced the same decrease
w3 xin H CGS 21680 binding in native and DTT-treated
membranes.
Furthermore, if TNM induced oxidation of cys-
teine residues at binding sites, the reducing agent
DTT, applied to modified receptors, should restore
their original properties. Treatment with DTT did not
restore the properties of the TNM-modified receptors,
thus excluding the possibility that TNM modified
cysteine residues under these experimental condi-
tions.
Experiments carried out at pH 6.5 did not exclude
the presence of other modifiable residues, probably
cysteines: when TNM modification was performed at
w3 xpH 6.5, we observed a higher level of H CGS
21680 binding inactivation than at pH 8.1. However,
the agonist and antagonist ligands were unable to
protect the sites from reagent modifications, indicat-
ing that no residues are located on the adenosine A 2A
ARs sites. Studies are required to better clarify the
w3 xinvolvement of cysteine residues in H CGS 21680
binding.
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